Pulmatrix Will Present Promising New Data at the North American Cystic Fibrosis Conference on October 27-29, 2016
New study shows that Pulmatrix's inhaled drug delivery platform successfully delivers higher doses of an antifungal drug to the lungs compared to oral delivery.
LEXINGTON, Mass., Oct. 11, 2016 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) will present promising new preclinical data about its inhaled antifungal drug PUR1900 in a poster at the North American Cystic Fibrosis Conference.
"The preclinical study comparing PUR1900 to the oral reference product shows that PUR1900 offers a significant advantage over the current standard of care for treating fungal infections in the lungs," said David Hava, Ph.D., Chief Scientific Officer for Pulmatrix.
Cystic fibrosis patients frequently suffer from a condition called allergic bronchopulmonary aspergillosis (ABPA), an allergic disease caused by fungal infections, which is often treated with oral antifungals, such as itraconazole. High oral doses are needed to get enough of the antifungal drug to the lungs through the bloodstream to fight the infection, resulting in the potential for severe side effects that must be managed and monitored—including liver toxicity.
Pulmatrix's inhaled drug PUR1900, which combines itraconazole with the company's dry powder delivery technology platform, has the potential to solve these problems by delivering the drug directly to the lungs. The new study confirms the expected advantages of inhaled drug delivery.
"The profile of PUR1900 demonstrated in this study, with high lung exposure and low systemic levels, should be well suited for treating fungal infections. Our goal is to translate this profile in our upcoming clinical trials which will help us establish optimal dosing parameters for patients," explained Dr. Hava.
The poster will be presented during the conference in the Orange County Convention Center in Orlando, Florida, October 27-29.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for lung diseases, including opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, an inhaled antifungal that could benefit severe asthmatics and patients with rare disease like cystic fibrosis. Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 10, 2016. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
William Duke, CFO
Chris Brinzey, Westwicke Partners
SOURCE Pulmatrix, Inc.